04:27 AM EDT, 08/08/2025 (MT Newswires) -- Crinetics Pharmaceuticals ( CRNX ) reported a Q2 loss late Thursday of $1.23 per diluted share, wider than a loss $0.94 a year earlier.

Four analysts polled by FactSet expected a loss of $1.13.

Revenue for the quarter ended June 30 was $1 million compared with $399,000 a year earlier.

Analysts surveyed by FactSet expected $600,000.

The company said its cash, cash equivalents, and investments totaled $1.2 billion as of June 30, sufficient to fund its operations into 2029.

Crinetics shares were up nearly 12% in recent premarket activity Friday.